CVI
Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wedege, E.
Right arrow Articles by Zollinger, W. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wedege, E.
Right arrow Articles by Zollinger, W. D.

 Previous Article  |  Next Article 

Clinical and Diagnostic Laboratory Immunology, July 1999, p. 639-642, Vol. 6, No. 4
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.

Redesignation of a Purported P1.15 Subtype-Specific Meningococcal Monoclonal Antibody as a P1.19-Specific Reagent

E. Wedege,1,* D. A. Caugant,2 A. Musacchio,1,dagger N. B. Saunders,3 and W. D. Zollinger3

Department of Vaccinology1 and WHO Collaborating Centre for Reference and Research on Meningococci, Department of Bacteriology,2 National Institute of Public Health, N-0403 Oslo, Norway, and Department of Bacterial Diseases, Walter Reed Army Institute of Research, Walter Reed Army Medical Center, Washington, D.C. 20307-51003

Received 4 February 1999/Returned for modification 25 March 1999/Accepted 21 April 1999

Two reference monoclonal antibodies against the meningococcal P1.15 subtype PorA, MN3C5C and 2-1-P1.15, showed only partial concordant recognition of meningococcal isolates. Cyanogen bromide cleavage of P1.19,15 PorA, peptide mapping, and sequencing of porA regions demonstrated that 2-1-P1.15 was specific for subtype P1.19, and henceforth it is to be redesignated as 2-1-P1.19.

* Corresponding author. Mailing address: Department of Vaccinology, National Institute of Public Health, P.O. Box 4404 Torshov, N-0403 Oslo, Norway. Phone: 47 22 04 26 99. Fax: 47 22 04 23 01. E-mail: elisabeth.wedege{at}folkehelsa.no.

dagger Present address: Department of Vaccines, Center for Genetic Engineering and Biotechnology, Havana 10600, Cuba.

Clinical and Diagnostic Laboratory Immunology, July 1999, p. 639-642, Vol. 6, No. 4
1071-412X/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
Antimicrob. Agents Chemother. Clin. Microbiol. Rev. Infect. Immun.
J. Clin. Microbiol. J. Virol. ALL ASM JOURNALS

Copyright © 1999 by the American Society for Microbiology. All rights reserved.